Quoin Pharmaceuticals Ltd DRC - Asset Resilience Ratio
Quoin Pharmaceuticals Ltd DRC (QNRX) has an Asset Resilience Ratio of 69.58% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See QNRX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2025)
This chart shows how Quoin Pharmaceuticals Ltd DRC's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Quoin Pharmaceuticals Ltd DRC.
Liquid Assets Composition Over Time
This chart breaks down Quoin Pharmaceuticals Ltd DRC's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Quoin Pharmaceuticals Ltd DRC for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $10.92 Million | 69.58% |
| Total Liquid Assets | $10.92 Million | 69.58% |
Asset Resilience Insights
- Very High Liquidity: Quoin Pharmaceuticals Ltd DRC maintains exceptional liquid asset reserves at 69.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Quoin Pharmaceuticals Ltd DRC Industry Peers by Asset Resilience Ratio
Compare Quoin Pharmaceuticals Ltd DRC's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Quoin Pharmaceuticals Ltd DRC (2015–2025)
The table below shows the annual Asset Resilience Ratio data for Quoin Pharmaceuticals Ltd DRC.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 73.21% | $14.93 Million | $20.39 Million | +6.79pp |
| 2024-12-31 | 66.42% | $10.43 Million | $15.71 Million | -1.74pp |
| 2023-12-31 | 68.15% | $8.29 Million | $12.17 Million | -0.96pp |
| 2022-12-31 | 69.12% | $9.99 Million | $14.46 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $9.36 Million | -- |
| 2017-12-31 | 46.09% | $4.03 Million | $8.75 Million | -26.62pp |
| 2016-12-31 | 72.71% | $6.41 Million | $8.81 Million | +14.12pp |
| 2015-12-31 | 58.60% | $2.01 Million | $3.43 Million | -- |
About Quoin Pharmaceuticals Ltd DRC
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company's lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrom… Read more